Anti-REGN5381 Reference Antibody (Imelciment, RUO) (HB010036)

Name: Anti-REGN5381 Reference Antibody (Imelciment, RUO)
Brand: abinScience
SKU: HB010036
Price: 490 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD): --

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HB010036
Description	Anti-REGN5381 Reference Antibody (Imelciment, RUO) (HB010036) is a human monoclonal antibody detecting NPR1/NPR-A. Expressed in Mammalian cells.
Species reactivity	Human
Applications	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Host species	Human
Clonality	Monoclonal
Isotype	Immunoglobulin (H-gamma4_L-kappa)_G4hCH2CH3
Biological activity	Vixticibart specifically binds to human and monkey natriuretic peptide receptor 1 extracellular domain proteins, with no cross-reactivity to mouse natriuretic peptide receptor 1, natriuretic peptide receptor 2, or natriuretic peptide receptor 3, and does not interfere with atrial natriuretic peptide binding to human natriuretic peptide receptor 1 [1]. Vixticibart (10 -12 to 10 -6 M; under conditions supporting binding) dose-dependently binds to human and monkey natriuretic peptide receptor 1-expressing HEK293 cells, with enhanced binding in the presence of atrial natriuretic peptide or brain natriuretic peptide, and EC 50 values ranging from 2.27 to 5.69 nM [1]. Vixticibart (10 -15 to 10 -5 M) dose-dependently agonizes human and monkey natriuretic peptide receptor 1 in a calcium flux bioassay, with EC 50 values ranging from 42.5 to 82.2 nM, and achieves maximum activation comparable to natriuretic peptide ligands at high concentrations [1]. Vixticibart (10 -14 to 10 -5 M) dose-dependently activates human natriuretic peptide receptor 1 to induce cGMP accumulation in HEK293 cells, acts as a partial agonist relative to natriuretic peptide ligands, and shows enhanced activation in the presence of low concentrations of atrial natriuretic peptide or brain natriuretic peptide [1]. Vixticibart (molar excess; overnight at 4°C) binds to the N-terminal domain of human NPR1 dimers, stabilizing an active conformation in the presence of atrial natriuretic peptide and an active-like conformation in the absence of atrial natriuretic peptide, which drives downstream signaling [1]. Vixticibart (1-50 mg/kg; s.c.; single dose) induces a 10-15 mm Hg reduction in systolic blood pressure in normotensive NPR1 hu/hu mice, with dose-dependent duration of effect lasting up to 28 days for the 50 mg/kg dose [1]. Vixticibart (25 mg/kg; i.v.
Expression system	Mammalian cells
Nature	Recombinant
Target	Vixticibart
Endotoxin level	< 10 EU/mg as determined by LAL method.
Purity	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	CAS: 2845128-05-2
Form	Liquid
Storage buffer	0.01M PBS pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	Idiotypic, 2845128-03-0
Background	Atrial natriuretic peptide receptor 1 (NPR1/NPR-A) is a ~118 kDa protein. Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Plays an essential role in the regulation of endothelial cell senescence and vascular aging. Upon activation by ANP or BNP, stimulates the production of cyclic guanosine monophosphate (cGMP) that promotes vascular tone and volume homeostasis by activation of protein kinase cGMP-dependent 1/PRKG1 and subsequently PRKAA1, thereby controlling blood pressure and maintaining cardiovascular homeostasis. 1. Liu, S. et al. (2025) Nature structural & molecular biology 32, 469-478. PMID: 39543315 2. Long, C. et al. (2022) Aging cell 21, e13699. PMID: 36016499
References	1. Dunn ME, et al. Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone. Nature. 2024;633(8030):654-661. [HB010036] 2. Dunn M, et al. A novel agonist antibody to membrane-bound guanylate cyclase receptor, natriuretic peptide receptor 1, induces sustained vasodilation[J]. 2023. [HB010036] 3. Kithcart A P, et al. Effects of REGN5381, a natriuretic peptide receptor 1 agonist antibody, in hypertensive mouse models and mildly hypertensive but otherwise healthy adults in a phase 1 first-in-human study[J]. Journal of the American College of Cardiology, 2024, 83(13_Supplement): 1706-1706. [HB010036]
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG4 (S228P) Recombinant Isotype Control Antibody (13R4) (HP298207)

Images

SDS-PAGE

SDS-PAGE for Research Grade Imelciment

References

Datasheet

Anti-REGN5381 Reference Antibody (Imelciment, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Recombinant Proteins

Antibodies

Assay Kits

Anti-REGN5381 Reference Antibody (Imelciment, RUO) (HB010036)

Overview

Images

References

Datasheet

SDS